PNB, Trent, TVS Motor, Shriram Finance, and Zydus Lifesciences will replace these five stocks in the Nifty Next 50 index, effective from September 29, 2023.
The share price of the drugmaker has risen 92% in the last one year from its 52-week low of ₹340.60 touched on July 27, 2022.
The USFDA has allowed Zydus to manufacture and market Estradiol Transdermal System USP in the U.S; the drug will be produced at the group’s facility in Moraiya, Ahmedabad.
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
The Ahmedabad-based pharma company has received seven approvals from the U.S. drug regulator so far in October.
The Sensex and Nifty are set to open lower on Monday, following weak cues from Asian peers and a negative finish on Wall Street on Friday.
